#Trusted Medical Treatment Facilitator in Switzerland

[swisshealthclinic]

Navigating Healthcare in Germany: The Role of a Trusted Medical Treatment Facilitator

Finding the Right Care in Germany: The Importance of a Medical Treatment Facilitator

Germany, renowned for its world-class medical advancements and rigorous healthcare standards, has become a sought-after destination for patients seeking specialized treatments. However, navigating the Trusted Medical Treatment Facilitator in Germany can be complex, especially for international patients unfamiliar with the language, culture, and regulations. This is where a trusted medical treatment facilitator comes in.

What is a Medical Treatment Facilitator?

A medical treatment facilitator is a professional who bridges the gap between international patients and German healthcare providers. They offer a range of services, including:

Patient Coordination: Facilitators help patients schedule appointments with specialists, arrange accommodations, and coordinate transportation.

Medical Consultation: They can connect patients with German doctors for initial consultations and obtain second opinions.

Treatment Planning: Facilitators assist in creating personalized treatment plans based on patients' needs and medical history.

Insurance Assistance: They can help patients navigate the German healthcare insurance system and ensure that their coverage is adequate.

Cultural Orientation: Facilitators provide guidance on German customs, etiquette, and communication styles.

Why Choose a Medical Treatment Facilitator?

There are several compelling reasons to work with a medical treatment facilitator when seeking healthcare in Germany:

Expertise and Experience: Facilitators have in-depth knowledge of the German healthcare system and can provide valuable insights and recommendations.

Language Barrier: For patients who do not speak German, a facilitator can act as a translator, ensuring effective communication with healthcare providers.

Time and Stress Reduction: Facilitators can save patients time and reduce stress by handling administrative tasks and coordinating appointments.

Access to Specialized Care: Facilitators can help patients connect with top-tier specialists and clinics, even for rare or complex conditions.

Personalized Service: A good facilitator will provide personalized attention and support throughout the entire treatment process.

Key Factors to Consider When Choosing a Facilitator

When selecting a medical treatment facilitator, there are several important factors to consider:

Experience and Reputation: Look for a facilitator with a proven track record and positive testimonials from previous clients.

Network of Providers: Ensure that the facilitator has a strong network of reputable healthcare providers in Germany.

Language Proficiency: The facilitator should be fluent in both English and German to facilitate effective communication.

Transparency and Honesty: Be wary of facilitators who make unrealistic promises or charge excessive fees.

Personalized Approach: The facilitator should be willing to listen to your needs and tailor their services accordingly.

The Benefits of Seeking Treatment in Germany

Germany offers several advantages for patients seeking specialized medical care:

World-Class Medical Facilities: German hospitals and clinics are renowned for their state-of-the-art equipment and highly skilled professionals.

Advanced Medical Treatments: Germany is at the forefront of medical research and innovation, offering access to cutting-edge treatments and therapies.

High Quality of Care: German healthcare providers are committed to providing the highest quality of care and patient satisfaction.

Competitive Costs: While healthcare costs in Germany can be high, they are often comparable to those in other developed countries, especially when considering the quality of care.

Conclusion

A trusted medical treatment facilitator can be invaluable for international patients seeking healthcare in Germany. By providing expert guidance, coordination, and support, facilitators can help patients navigate the complex German healthcare system and receive the best possible care. If you are considering seeking treatment in Germany, working with a reputable facilitator can make the process smoother and more rewarding.

[biotechtimes]

Submit Innovative Ideas: C-CAMP COVID-19 Innovations Deployment Accelerator

New Post has been published on https://biotechtimes.org/2020/04/06/submit-innovative-ideas-c-camp-covid-19-innovations-deployment-accelerator/

Submit Innovative Ideas: C-CAMP COVID-19 Innovations Deployment Accelerator

C-CAMP has announced C-CAMP COVID-19 Innovations Deployment Accelerator in which you can submit innovative ideas to fight against COVID-19. COVID-19 Innovations Deployment Accelerator.

C-CAMP COVID-19 Innovations Deployment Accelerator

COVID-19 outbreak has wreaked havoc across the world with ramifications poised to surpass any catastrophe in our living memory. We believe that the fightback will start with your out-of-the-box innovative solutions and our ecosystem to change the course of this raging pandemic.

C-CAMP has launched C-CAMP COVID-19 Innovations Deployment Accelerator or C-CIDA on 26th March 2020 to help accelerate COVID-19 innovations stuck in last-mile issues. The initiative by C-CAMP has now been joined by multiple partners:- UNHIE, Social Alpha, XYNTEO India2022, MedTechConnect, India Health Fund, AIC CCMB and CCMB and the latest addition, PATH. 

C-CIDA has announced a search for innovations that are ready to be deployed immediately or in the near future to curb the COVID-19 outbreak. 

Based on the assessment, we will help in 

fast-tracking promising innovations for pilot deployment, scaling through industry partnership, navigating regulatory pathway and connecting with investors. 

Selected innovations will get��fast track technology assessment or HTA and an opportunity to get scale-up investment and implementation as facilitated by United Nations Health Innovation Exchange or UNHIE.

Support in industrial/manufacturing opportunities through India2022 and MedTechConnect networks.

Opportunity to raise funding from India2022 partners. 

Support towards operational validation and field implementation to facilitate entry into the healthcare systems from PATH 

The assessment criteria will include readiness for deployment, scientific validity, feasibility, and impact. Assessment will happen daily. In the next few days, we will select and help most impactful innovations that are quickest to deploy. 

Innovations can be under following categories: screening, diagnostics, therapeutics, vaccines, containment strategies, public health & other categories including but not limited to focussed technologies in 

mobile health technologies for screening and homecare, 

diagnostic kits and Point of Care tests, 

protective gear and sterilization innovations for care providers, 

digital triaging tools and risk stratifying systems, 

low cost ventilators and oxygen therapy units, 

AI systems to assist critical care, 

supply chain innovations, 

volunteerism and service innovations and 

scalable plug and play isolation units, treatment tents

Submit an executive summary of your innovation here

Confidentiality commitment: Information submitted using this form will be treated as strictly confidential; however, if you have any specific IP related concerns, kindly share non-confidential information only.

For more information, please write to: covid19innovations[at]ccamp.res.in

C-CIDA Partners: 

About C-CAMP Centre for Cellular and Molecular Platforms (C-CAMP): C-CAMP is a member of the Bangalore Life Sciences Cluster (BLiSC) with a mandate to enable cutting-edge life science research and innovation, and promote life science entrepreneurship. It is India’s premier innovation and technology hub as well as one of the largest and most thriving life sciences incubators in the country. C-CAMP has directly funded, incubated and mentored close to 150 start-ups over the last few years and is connected to about 1000 startups and entrepreneurs across the country in healthcare, agriculture and environment. C-CAMP is an initiative supported by the Department of Biotechnology, Ministry of Science and Technology, and NITI Aayog, GoI. Find more details on www.ccamp.res.in

About UN Health Innovation Exchange: UNHIE is a new initiative by UNAIDS and partners to leverage the potential of innovations to improve the health of all. The Health Innovation Exchange will link innovators to investors and innovations to implementers. Launched on the sidelines of the World Health Assembly in Geneva, Switzerland, the initiative aims to support global efforts to reach the Sustainable Development Goals. To respond to demands from countries, over the coming months UNAIDS will facilitate country-level innovation exchanges in key countries. Those exchanges will identify specific health-related challenges and areas in which innovation and technology could transform access to health care. For more details please visit: http://www.healthinnovation2030.org

About Social Alpha: Social Alpha promotes innovations and entrepreneurship with a mission to create large scale social, economic and environmental impact. Social Alpha nurtures start-ups through their lab to market journey, helping them create high quality, commercially viable, accessible and affordable solutions. Foundation for Innovation and Social Entrepreneurship (FISE) forms the core of the Social Alpha architecture and operates through a nationwide network of technology and business incubation infrastructure sponsored and enabled by Tata Trusts, Government of India and several academic, philanthropic and corporate partnerships. Social Alpha is focused on catalyzing entrepreneurship for impact and provides critical technology and business incubation support to the mission-driven start-ups. For more information, please visit www.socialalpha.org. 

About Xynteo: Xynteo is an advisory firm working with global companies to identify and carry out projects enabling our mission of reinventing growth. India2022, powered by Xynteo, is a purpose-driven global coalition committed to creating proof points for a new model of growth by 2022, the 75th year of India’s independence. The Aditya Birla Group, Hindustan Unilever, Shell, TechnipFMC, Baker Hughes, WPP, State Bank of India, Cyient and Tata Trusts have committed to this bold goal and are the current partners of the India2022 coalition. The coalition was launched in March 2017 with blessings from the then President of India, Shri Pranab Mukherjee who praised this initiative as “the need of the hour”. Currently, India2022 partners are working to develop projects across four impact tracks including Energise, Waste and Sanitation, Healthcare and Sustainable Mining https://xynteo.com 

About MedTechConnect: MedTechConnect platform is designed to strengthen the ecosystem in India by bringing together innovative healthcare solutions, disruptive delivery models, and pioneering funding models to make critical medical technologies accessible to everyone. India is home to a thriving technology ecosystem, yet more than 80% of its medical technologies are imported. A large segment of the country’s population still does not have access to basic healthcare services. To combat these challenges, Cyient and India2022 (powered by Xynteo) have partnered to build MedTechConnect, a platform that brings all MedTech stakeholders together to address India’s ‘last-mile challenge’ in healthcare and touch 10 million lives by 2022 https://www.medtechconnect.in

About AIC-CCMB: Atal Incubation Centre – Centre for Cellular & Molecular Biology (AIC-CCMB) is an incubator dedicated to providing a thriving ecosystem for start-ups and scientists with early-stage technologies in life sciences through funding opportunities, latest biologics equipment, mentorships and financial advice. A place where innovators and start-ups in Healthcare, Pharmaceuticals and Biotechnology can find business support services and a hand holding network necessary to take their idea to the next level. With a history of successful home-grown enterprises, CSIR – CCMB has always fostered the spirit of entrepreneurship. We are sowing the capital of our combined knowledge of scientific research, product development, and business development to help startups succeed. We harness our insight, experience, and expertise in helping entrepreneurs to achieve their goals. It is our aim to transform scientific research into successful start-ups that can help alleviate the quality of life of the general population and mitigate some of the world’s biggest challenges in healthcare, food and animal care. Innovations in life sciences are critical to “Make in India” specifically to improve the quality of life of the general population. At AIC-CCMB, we endeavor to build an ecosystem to enable biotechnology innovation. As Indian researchers and innovators begin to expand the boundaries of science, pursuing novel therapies, diagnostics, medical devices and industrial solutions, we want to ensure that their technologies are translated into sustainable business solutions that reach the citizens. http://aic.ccmb.res.in 

About CCMB: Centre for Cellular and Molecular Biology under the Council of Scientific & Industrial Research (CSIR) is a premier research organization engaged future-forward areas of modern biology. The Centre conducts high-quality basic research and training in modern biology, and promotes centralized national facilities for new and modern techniques in the inter-disciplinary areas of biology. Its mission is to conduct research in frontier and multi-disciplinary areas of modern biology and to seek potential applications of this work. CSIR -CCMB has a mandate to train people in the advanced areas of biology to serve the needs of development in these areas, with special provision for short-term training of staff from other institutions in techniques for which adequate facilities may not exist elsewhere. This centre provides centralized facilities in the country for new and modern techniques in the inter-disciplinary areas of biology, and to ensure that these facilities are so organized, maintained and administered that they can be put to maximal use by research workers from other laboratories and institutions in the country. https://www.ccmb.res.in 

About India Health Fund: The India Health Fund (IHF) was set up by Tata Trusts in strategic partnership with The Global Fund. The Trusts seeded the IHF with an initial corpus of US$ 15 million, with a target of raising an additional US$ 135 million over the next five years to invest in innovations to eliminate TB, Malaria and other infectious diseases in India. The Fund’s primary goal is to aggregate resources towards fostering innovations to accelerate progress towards the elimination of Tuberculosis (TB) by 2025 and Malaria by 2030, by enabling their lab to the last-mile journey. http://www.indiahealthfund.org

About PATH: PATH is a global public health organization working to accelerate health equity so all people and communities can thrive. We advise and partner with public institutions, businesses, grassroots groups, and investors to solve the world’s most pressing health challenges. PATH works in more than 70 countries to transform bold ideas into sustainable solutions that improve health and well-being for all. https://www.path.org

View Notification

[babymilkaction]

Multi-stakeholder partnerships: what are the risks? The case of Scaling up Nutrition (SUN)

Multi-stakeholder partnerships: what are the risks? The case of Scaling up Nutrition (SUN)

PDF

The potential of partnerships with the private sector has dominated the narrative of the 2030 Agenda for Sustainable Development, with Sustainable Development Goal (SDG) 17 overshadowing many of the other key dimensions. Multi-stakeholder partnerships (MSPs) are considered “important vehicles for mobilizing and sharing knowledge, expertise, technologies and financial resources to support the achievement of the sustainable development goals in all countries, particularly developing countries”.(2) Concerns about the possible implications of too close relations with the private sector and the blurring of roles and responsibilities precipitated by the MSP approach, are often rejected as out-dated, ideology-driven and anti-corporate. This is despite the limited evidence of the positive contribution of such approaches, nor assessments of the risks they may pose to governance and human rights.(3) A prominent example in the area of food security and nutrition is the Scaling up Nutrition (SUN) ‘Movement’ – an initiative that brings together governments, UN agencies, donors, business and civil society in a “collective action to improve nutrition”.(4) SUN’s members include the UN, Civil Society, Governments and food, beverage and agro-chemical companies, two of which sit on its International Lead Group.(5) Launched in 2010, to date, 61 countries have signed on to SUN and the initiative has substantial political and financial backing. The Bill & Melinda Gates Foundation (BMGF), as well as several bilateral donors 6 and the EU are key funders of SUN. SUN’s theory of change to end malnutrition requires ‘multi-stakeholder’ platforms at the national level as a key element. SUN also proposes that donor funding can be galvanized through building consensus on scientific and ‘evidence-based’ strategies. Following the lead of the BMGF-funded 2008 series in the Lancet on Maternal and Child Undernutrition, revised in 2013, the majority of SUN’s recommended interventions involve fortified products and supplements of some kind.(7) A research study based on three country case studies (Uganda, Guatemala and India) investigating the impact of SUN on the right to adequate food and nutrition found the following serious concerns:(8)

1. Restructuring of governance – paving the way for private sector influence

SUN promotes trust in collaborative arrangements with the private sector, opening up policy space to it with no acknowledgment of the risks.(9) Most SUN countries have no effective mechanisms to address Conflicts of Interest (COI).(10) SUN’s use of the rhetoric of ‘inclusiveness’ relies on the ‘management’ rather than ‘avoidance’ of COI. Its COI tool has many flaws (11)and creates confusion rather than serving the purpose of helping governments avoid COI.(12)

2. Democratic deficits and top-down,  elitist leadership

Most countries join SUN with a simple letter of commitment with no requirement for democratic scrutiny of the implications for governance. SUN interventions were found to be ‘top-down’ with civil society represented by a select group of international NGOs, mostly engaged in service delivery, with no recognition of power differentials between and within ‘stakeholder’ groups. SUN’s international Lead Group includes large transnational corporations and allows them  direct influence over SUN’s policy direction. The Lead Group moreover includes key advocates of technical, private sector- or market-driven solutions to malnutrition, such as the Bill and Melinda Gates Foundation.(13, 14)

3. Lack of external scrutiny and accountability for actions

The monitoring and evaluation processes in SUN consist primarily of internal self-reflections (Joint Assessment Exercises). Under SUN’s principle of ‘mutual accountability’, members are accountable to one another rather than to communities affected. SUN’s recent Mid-Term Review also acknowledged that “there is a deficit in mutual accountability … In practice, SUN members who are significantly dependent on international assistance are more rigorously assessed than are the funding providers”.(15) SUN has no complaint mechanisms in place and great emphasis is placed on ‘dialogue’ should problems occur.16 Since SUN acts through governments and its members rather than directly, attribution for its impacts is difficult to establish. Indeed, no-one seems liable for actions promoted under SUN. Accountability towards people affected by SUN interventions is minimal.

4. Shifting the policy agenda: short-term medicalized nutrition interventions

SUN’s emphasis on “consensus” and the lack of mechanisms for dispute resolution can stifle dissenting opinions and weaken the drive to frame strategies that address more fundamental problems in food security and nutrition. SUN focuses on the first 1000 Days of a child (from conception to two years) emphasizing short-term medicalized, product-based interventions for the treatment of undernutrition. Little/no evidence was found that these interventions brought meaningful and long-term changes to the nutrition prospects of those affected by malnutrition, while there was some evidence of negative consequences on indigenous food cultures and confidence in local foods. SUN now claims to address malnutrition in all its forms, however SUN’s emphasis on fortification of single micronutrients and how this can lead to the promotion of ultra-processed foods through misleading claims received hardly any attention.17

5. Support for industrial agriculture rather than structural transformation of food systems

SUN’s bias towards technological solutions, in particular, biofortified seeds and fortified foods, entail important human rights risks for small-scale food producers, indigenous peoples, consumers and the planet. These solutions moreover ignore the structural causes of malnutrition and stand counter to / distract from strategies aimed at fundamentally re-shaping food systems in support of agro-biodiverse production, the rights of small-scale food producers, diversified and healthy diets, and planetary health.

Conclusion

SUN does not address the social, cultural, economic and political determinants of malnutrition and instead emphasizes short-term, technical interventions. The private sector influence at the core of SUN results in initiatives that largely benefit them. By joining SUN, countries risk foregoing strategies aimed at addressing the root causes of malnutrition such as unequal power relations, social exclusion, exploitation, poverty, discrimination, low wages, land grabbing, and abusive marketing of food products. SUN contributes to the consolidation of private sector influence on public food and nutrition policies. By shifting policy accountability from the state to multi-stakeholder platforms, the government is reduced to the role of facilitator, rather than the primary actor in addressing malnutrition. This makes it even more difficult for affected groups to hold the state accountable for compliance with its human rights obligations, and moves us further to a charity driven, rather than a rights-based approach to food and nutrition.

Notes

Black, R.E. et al. (2013): Maternal and child undernutrition and overweight in low-income and middle-income countries. In: The Lancet, Volume 382, Issue 9890, pp. 427-451. https://doi.org/10.1016/S0140-6736(13)60937-X

HLPE (2018): Multi-stakeholder partnerships to finance and improve food security and nutrition in the framework of the 2030 Agenda. A report by the High Level Panel of Experts on Food Security and Nutrition of the Committee on World Food Security. Rome. www.fao.org/3/CA0156EN/CA0156en.pdf

Martens, Jens/Seitz, Karolin (2015): Philanthropic Power and Development. Who shapes the Agenda? Aachen/Berlin/Bonn/New York: Brot für die Welt/Global Policy Forum/MISEREOR. www.globalpolicy.org/images/pdfs/GPFEurope/Philanthropic_Power_online.pdf

Mokoro Limited (2015): Independent Comprehensive Evaluation of the Scaling Up Nutrition Movement. Final Report. Main Report and Annexes. In partnership with Valid International & FEC Consulting Oxford. http://scalingupnutrition.org/wp-content/uploads/2015/05/SUN_ICE_FullReport-All(1-5-15).pdf MQSUN+ (2018): Midterm Review of the Scaling up Nutrition Movement: Final Report. 22 December 2018. London. https://scalingupnutrition.org/wp-content/uploads/2019/03/SUN-MTR-Final-Report-2019_external-1.pdf

Richter, J. (2015): Conflicts of interest and global health and nutrition governance – The illusion of robust principles. In: BMJ RR, 12 February 2015. www.bmj.com/content/349/bmj.g5457/rr

Schieck Valente, F. L. (2015): The Corporate Capture of Food and Nutrition Governance: A Threat to Human Rights and Peoples’ Sovereignty. In: Right to Food and Nutrition Watch: Peoples’ Nutrition is not a Business (2015), pp. 15-20. www.righttofoodandnutrition.org/files/Watch_2015_Article_1_The%20Corporate%20Capture%20of%20Food%20and%20Nutrition%20Governance.pdf

UK Health Forum (2018): Public health and the food and drinks industry: The governance and ethics of interaction. Lessons from research, policy and practice. London: UKHF. www.idrc.ca/sites/default/files/sp/Documents%20EN/ukhf-casebook-jan18.pdf

1 This briefing is based on a study conducted by FIAN International, IBFAN, and SID on the human rights impact of multi-stakeholder partnerships: the case of the Scaling up Nutrition Initiative. Forthcoming November 2019. 2 See https://sustainabledevelopment.un.org/sdinaction 3 HLPE (2018). 4 SUN Movement Strategy and Road Map (2016-2020), p. 6. 5 Royal DSM, a Dutch-based international chemical company producing micronutrient ingredients for the food and dietary supplements industry, and Java Foods, a Zambian company manufacturing instant fortified cereals and noodles. 6 Canada, France, Germany, Switzerland, Ireland, the Netherlands, Norway, the UK, and the USA. 7 Black et al. (2013). 8 This briefing is based on a study conducted by FIAN International, IBFAN, and SID on the human rights impact of multi-stakeholder partnerships: the case of the Scaling up Nutrition Initiative. Forthcoming November 2019. 9 For a recent compilation of case studies concerning collaboration with food and beverage industry in public health policy and COI, see UK Health Forum (2018) 10 ‘Institutional conflicts of interest arise when an institution’s own financial interest or those of its senior officials pose risks of undue influence on decisions involving the institution’s primary interests.’ Lo, B. and M. Field, Inst of Med. (US) Committee on Conflict of Interest in Medical Research, Education and Practice, Eds. (2009) 11 Amongst others, it uses an incorrect definition that confuses COI within an entity with conflicts caused by disagreements between entities 12 For a critic of SUN’s conflict of interest tool, see Richter (2015). 13 See, for instance, Martens/Seitz (2015). 14 A list of current Lead Group members can be found at: https://scalingupnutrition.org/sun-supporters/sun-movement-lead-group/ 15 MQSUN+ (2018), p. viii. 16 The Business Network has a whistleblower mechanism that can be used for registering alleged breaches of its Principles of Engagement by companies participating in SUN. Besides being extremely difficult to find, this mechanism concerns the activities of business and not the actions promoted under SUN. No information is provided as to whether the mechanism has ever been used and what measures have been taken in response. 17 https://www.who.int/ncds/prevention/en/

Multi-stakeholder partnerships: what are the risks? The case of Scaling up Nutrition (SUN) was originally published on Baby Milk Action

[addictionfreedom]

Addiction Treatment Center

Contents

Mountainside treatment center

Personalized care plans

Leading outcomes management

Drug treatment centers

10 drug rehabilitation facilities

Treatment center family

The Meadows is Most Trusted Addiction Treatment Center located in Arizona. For the last 40 years, it has been the Best Drug Rehab Center in Arizona as well …

drug and alcohol addiction treatment. Northeast addictions treatment center. NEATC is an Outpatient Drug Rehab and Alcohol Addiction Treatment Center in Quincy, Massachusetts.

Check out this story on courierpress.com: http://bit.ly/2AM9ecl …

Oct 3, 2018 … Lawsuits and deaths have drawn scrutiny and raise questions about oversight of the addiction-treatment industry.

Discover the ways an addiction is treated below to better understand what lies ahead. Calls to numbers dedicated to a specific treatment center profile will be routed to that treatment center.

mountainside treatment center has provided effective and innovative addiction treatment for 20 years. If you or a loved one needs alcohol or drug rehab, call us  …

Structured Treatment At the facility, trained addiction staff works with clients to instill hope that long-term recovery is possible. This facility provides structured addiction treatment and therapy in a single…

Addiction Treatment Centers Of America According to a statement released by Life Care Centers of America, The Highland’s parent company, Carlos Bonilla-Tejada has been named the facility’s newest director. "I have been very impressed with … Google began cracking down on addiction rehab ads last September following a report from … but only in the U.S. The new policy is

The Treatment Center of the Palm Beaches is a highly respected drug and alcohol addiction treatment services center for teens and adults located in sunny South Florida.

A bid to open a liquor store next door to veterans rehabilitation center in Queens just got cut off. The State Liquor Authori…

Treatment Centers XL has two drug treatment center locations in Colorado. Our drug and alcohol addiction treatment center in Denver CO is located on Albion Street and our new treatment center…

A liquor store has been denied its application to open next to a drug and alcohol rehab center in Queens, a bid that had the …

Find a rehab based on your drug, location and needs. Addiction Center provides info on addiction, treatment and recovery. Learn more about signs, symptoms, …

At New Life Addiction Treatment Center, we are constantly trying to better our therapy programs and introduce new therapy approaches to help you become addiction-free.

An inpatient addiction treatment center located in a pastoral setting that provides personalized care plans to support lifelong addiction recovery. Call us today at …

This site is authored by American Addiction Centers – a specialist in drug and alcohol addiction If it is a drug rehab center that is needed, T4A is the most comprehensive nationwide treatment facility…

Addiction Treatment Kansas <img src='http://bit.ly/2SQpPmm; alt='Detox Kansas City | addiction treatment health Kansas City | Detox Kansas City ‘ class=’alignleft’>Britt is now a defensive line coach for the kansas city chiefs … To a Judge in 2007, Garrett Explained His History with Add… The success with Sublocade during clinical trials in Kansas City helped the medication win FDA

We're accomplishing this through high-quality medication treatment led by … an individualized treatment plan for each patient suffering from opioid addiction.

by the Centers for Medicare & Medicaid Services (CMS) for 2019. "This QCDR designation further solidifies FOTO as the leading outcomes management solution in rehab therapy," says Christopher Hayes …

Suburban Hospital's Addiction Treatment Center offers a comprehensive program for the counseling and education for those suffering for substance abuse  …

At Addiction Treatment Services, we understand that the most important part of choosing a rehab center is finding the place that meets the individual's every need. Other important tasks we can…

TOP. Priscilla Rivera, Director 1500 Waters Place – Building #13. Bronx, New York 10461 (718) 904-0026 x 300 | (718) 597-9434. E-mail: …

Retreat Premier Addiction Treatment Centers provides residential treatment in Florida and Pennsylvania. Each facility is located within a close proximity to our outpatient locations, providing a…

a house remodeling project,” said Lancaster Rehab Center Administrator Amy Fish. Respite arrangements at Lancaster Rehab usually range from two weeks to three months. Respite residents get the …

Creedmoor Addiction Treatment Center is a 26 bed, short term inpatient addiction rehabilitation program which is medically supervised and staffed by a …

Sep 10, 2018 … See the best drug treatment centers across the nation here. �� Below is a list of Addiction Center's top 10 drug rehabilitation facilities in the …

Recovery Centers of America at Waldorf is a drug and alcohol rehab center offering addiction treatment to patients in Maryland, Virginia & Washington DC.

The Center for Integrated Health Solutions (US Dept. of Health & Human Services) … outpatient services, LAB ONE drug testing, assessments, treatment groups, …

Hazelden Betty Ford has 14 drug and alcohol addiction treatment centers in the U.S. with programs designed to meet your needs and lifestyle. Find a location …

Northeast Addictions is a Drug Rehab and Alcohol Addiction Treatment Center in Quincy, Massachusetts, minutes from Boston. Free Private Consultation 24/7.

Alcohol and drug treatment center ( an addiction rehab center) – what can you expect? Although this kind of therapy focuses on using a drug addicts beliefs to help them, it's still able to help addicts…

Suboxone Treatment Columbus Ohio Methadone, Suboxone, and Buprenorphine Doctors in Columbus, OH … eight withdrawal facilities in Columbus, Ohio who can facilitate a quick and safe detox  … COLUMBUS (WCMH … understand the scope of Ohio’s opioid crisis, and allocate resources accordingly. The bill also creates insurance regulation in which insurers must cover Medication Assisted treatme… A Drugmaker Tries

HARLINGEN — The city’s hospital district will soon welcome another major facility, a $6 million skilled nursing and rehabilit…

MISSOULA – A 91-year-old Lolo resident who was staying in a rehab center recovering from a fall recently had his home burglar…

Addiction Treatment Vt We are here for you. Center for Addiction Recognition Treatment Education Recovery. … Old Farm Rd. Stowe, VT 05672. 802-221-4939. Fax: 888-923-3476  … Vermont Addiction Treatment. Like other medical and psychiatric illnesses, addiction is a serious disease that should be treated by trained professionals. Finding the appropriate drug or alcohol… Nov 13, 2018 … “Vermont

PHILADELPHIA, Jan. 9, 2019 /PRNewswire/ — Life of Purpose Addiction Treatment Centers announced it has hired Dr. Tracy Blatt as its new Medical Director. Dr. Blatt is an alumna of Philadelphia Colleg…

Find word-class inpatient or outpatient rehab at Hazelden Betty Ford's premier addiction treatment center in Center City, Minnesota. Freedom from addiction …

(MENAFN – GetNews) Switzerland – Clinic Les Alpes a luxury rehab center in Switzerland , is experiencing significant growth as burnt out CEO’s and successful people with a drug or alcohol …

Neighbors listened worriedly Thursday to plans for a new drug treatment facility that could move into the space left by Sover…

Caron's success is centered on our family-focused addiction treatment and recovery plans. Our full-time, on-site, highly credentialed staff and dynamic, …

The Banyan treatment center family is comprised of facilities nationwide providing addiction treatment through numerous levels of care. Learn more about our …

The Treatment Center of the Palm Beaches is a highly respected drug and alcohol addiction treatment services center for teens and adults located in sunny  …

[vinayakmrfr1998-blog]

Global Flexible & Semi-rigid Ureteroscopy Market Study on Growth, Trends, Shares and Segmentation with Insights to 2023

Global Flexible & Semi-rigid Ureteroscopy Market Research Report, by Product (Flexible Ureteroscopes, Semi-rigid Ureteroscopes), Application (Therapeutic Applications), End-User (Hospitals, Clinics, Ambulatory Surgical Centers)– Global Forecast Till 2023

Market Highlights

The flexible and semi-rigid ureteroscopy market is expected to witness tremendous growth owing to the rising prevalence of kidney cancer, kidney stone, and change in lifestyle. Other key factors such as the growing consumption of alcohol, change to sedentary lifestyle, increasing dehydration, and obesity are contributing towards the growth of the market. According to the University Hospital Southampton NHS Foundation Trust, March 2016, the prevalence of renal stone treatment increased between 5 to 10% with a 75% increase in obese patients. However, factors such as high cost of ureteroscopy procedures are expected to hinder the market growth during the forecast period.

Free Report Sample At:

https://www.marketresearchfuture.com/sample_request/6469

Segmentation

The global flexible and semi-rigid ureteroscopy market is segmented on the basis of product, application, and end-user. The flexible and semi-rigid ureteroscopy market, by product, is categorized into flexible ureteroscopes, semi-rigid ureteroscopes, and rigid ureteroscopes. Flexible ureteroscopes are further segmented into fiberoptic ureteroscopes and digital ureteroscopes. On the basis of application, the market is segmented into therapeutic applications and diagnostic applications. Therapeutic applications are further segmented into urinary stricture, urolithiasis, and kidney cancer. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, ambulatory surgical centers, research centers, and others.

Browser Report At:

https://www.marketresearchfuture.com/reports/flexible-semi-rigid-ureteroscopy-market-6469

Regional Analysis

The Americas leads the market owing to the increasing prevalence of urolithiasis, increasing research and development programs in flexible video-ureteroscopes, and growing healthcare expenditure. The American Urological Association, July 2016, has estimated a 3% prevalence rate for kidney stone in all individuals and stated that it affects 12% of the population during their lifetime. Such a high rate of kidney stone drives the market growth in this region.

Europe is expected to be the second largest flexible and semi-rigid ureteroscopy market during the forecast period. The increasing occurrence of kidney cancer and obesity drive the market in this region. According to Cancer Research UK in 2015, there were12,547 new cases of kidney cancer. Thus, the growing cases of kidney cancer facilitate the market growth.

Asia-Pacific was estimated to be the fastest growing region for the global flexible and semi-rigid ureteroscopy market in 2017. The market is expected to witness high growth owing to the rising prevalence of obesity and kidney cancer in this region. According to the National Center for Biotechnology Information publication 2016, 121,099 cases of kidney cancer were recorded in Asia in 2012 in which 66.12% patients were males. Such a high prevalence of kidney cancer influences the market growth.

This is expected to provide favorable backgrounds for the market to grow.

The Middle East and Africa accounts for the low share due to lack of awareness, low per capita income, and lack of well-trained healthcare professionals. However, the rising oncology and health care services in hospitals and in the community are expected to influence the market in a positive way.

Key Players

Some of the key players in the global flexible and semi-rigid ureteroscopy market are Stryker (US), Olympus Corporation (Japan), Boston Scientific (US), Richard Wolf (Germany), KARL STORZ (Switzerland), ELMED Medical Systems (Turkey), Maxer Endoscopy (Germany), Rocamed (France), Vimex Endoscopy (Poland), ProSurg (US), and others.

NOTE: Our team of researchers are studying Covid19 and its impact on various

industry verticals and wherever required we will be considering covid19 footprints

for a better analysis of markets and industries. Cordially get in touch for more

details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

[csrgood]

International Research Partnership and EDCTP to Invest €44m in Next-generation Antimalarials to Combat Drug-resistant Malaria in Africa

The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV). The consortium will support the development of new treatments for malaria in the most-at-risk populations, including babies, patients with severe malaria, and those with drug-resistant infections. The EDCTP grant of €21.9 million is to be matched by funding from MMV, Novartis and partners. Over a period of five years, the grant will support the development of a portfolio of projects executed under the umbrella of the PAMAfrica research consortium. Clinical trial capabilities in Africa will also be strengthened to ensure each site involved can effectively operate to��ICH-GCP regulatory standards. The consortium includes seven research organizations from Burkina Faso, Gabon, Germany, Mozambique, Spain and Uganda. In addition to Novartis, other pharmaceutical company partners may join the consortium.

The PAMAfrica research consortium will conduct three clinical trials, supporting efforts to build clinical capacity and train scientists across Africa. One trial will explore new combinations of compounds, including new chemical classes, for the treatment of uncomplicated malaria in adults and children. These compounds are all known to be fully active against all drug-resistant strains, including the artemisinin-resistant Kelch13 strains.

The second trial will evaluate a new generation, rapid-acting treatment for severe malaria, cipargamin, also known as KAE609, which is being developed by Novartis, supported by a grant from the Wellcome Trust. In the third study, a novel formulation/ratio from Novartis of the current gold standard treatment artemether-lumefantrine will be tested in newborn infants weighing less than 5 kg or who are malnourished.

Dr Timothy Wells, Chief Scientific Officer of MMV and the coordinator of the PAMAfrica group, said: “All three of these research projects address areas of urgent need in malaria treatment. Antimalarial drug resistance, originally seen in Southeast Asia, is being reported in Africa and may threaten current treatments. It is important to have new therapies that are active against this emerging threat of resistance. The work on newborn infants and in severe malaria is groundbreaking in bringing medicines to this neglected group. Thanks to this critical support from EDCTP we are not only able to bring together the necessary African and European expertise to conduct these projects to address unmet needs, but in doing so, we are also able to support the training and development of the next-generation of leaders in clinical malaria research in Africa.”

Dr Michael Makanga, Executive Director of EDCTP, said: “Malaria continues needlessly to take 405,000 lives a year and must remain a global and national priority in endemic countries. We hope our funding for PAMAfrica will contribute to the development of successful new treatments that will support malaria eradication, while supporting the development of African research capacity.”

Caroline Boulton, Global Program Head, Malaria, Novartis, said: “Despite advances in malaria control, we still have a long way to go. New antimalarials are urgently needed to tackle rising parasite resistance to current therapies. In response, Novartis has committed to advance research and development of a number of next-generation antimalarial treatments. Partnerships play a critical role in helping to bring these novel agents forward and we sincerely appreciate the crucial support of EDCTP to this process.”

The PAMAfrica consortium

Recent reports from the World Health Organization (WHO) and the Lancet Commission on Malaria Eradication have made clear that defeating malaria will demand new tools, including new and better medicines. The 2019 WHO World Malaria Report states that global malaria deaths are declining at a slower rate than in recent years and highlights the need for improved interventions to treat the most vulnerable populations, including babies.

The PAMAfrica consortium was created to take up this challenge and implements a flexible portfolio approach to the development of new malarials. It brings together expertise from its various African and European partners. The consortium activities will be publicised under a dedicated logo.

The following organisations are partners in the PAMAfrica consortium:

Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon

https://cermel.org

Dr Ghyslain Mombo-Ngoma, Head of Clinical Operations Department

Centre National de la Recherche Scientifique et Technologique (CNRST) - Institut de Recherche en Sciences de la Santé (IRSS) - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Burkina Faso

http://www.urcn.net/index.php/en/

Prof. Halidou Tinto, Regional Director

    Eberhard Karls Universität Tübingen (EKUT), Germany

www.medizin.uni-tuebingen.de/de/startseite

Prof. Peter Kremsner Director Institute of Tropical Medicine

Manhiça Health Research Centre, Mozambique

http://manhica.org/wp/

Dr Eusebio Macete, Director

Fundación Privada Instituto de Salud Global de Barcelona (ISGlobal), Spain

https://www.isglobal.org/en/

Dr Quique Bassat, Head of the Malaria Programme

Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso

https://gras.bf/

Dr Alfred Tiono, Clinician and Senior Scientist

Infectious Diseases Research Collaboration (IDRC), Tororo, Uganda

http://idrc-uganda.org/

Dr Yeka Adoke, Epidemiologist

Medicines for Malaria Venture, Geneva, Switzerland

www.mmv.org

Dr Timothy Wells, Chief Scientific Officer

Novartis, Basel, Switzerland

www.novartis.com/global-health/malaria

Caroline Boulton, Global Program Head , Malaria, Global Health Development Unit

About MMV

Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in antimalarial drug research in its 20th year. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Since its foundation, MMV and partners have developed and brought forward eleven new medicines estimated to have saved around 2.2. million lives.

For more information visit www.mmv.org or contact Elizabeth Poll, Interim Director of Communications, via +41 79 709 59 92 or polle@mmv.org

About EDCTP

EDCTP aims to support collaborative research that accelerates the clinical development of new or improved interventions to prevent or treat HIV/AIDS, tuberculosis, malaria and neglected infectious diseases in sub-Saharan Africa.The second EDCTP programme is implemented as part of the European Framework Programme for Research and Innovation, Horizon 2020.

For more information visit www.edctp.org or contact Gert Onne van de Klashorst, Communication Officer via +31 70 344 0885 or media@edctp.org

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.

For more information visit www.novartis.com or contact media.relations@novartis.com

source: https://www.csrwire.com/press_releases/43817-International-Research-Partnership-and-EDCTP-to-Invest-44m-in-Next-generation-Antimalarials-to-Combat-Drug-resistant-Malaria-in-Africa?tracking_source=rss

[vishwanathblr-blog]

Flexible and Semi-rigid Ureterostomy Market Research Report – Forecast to 2023

Title Flexible and Semi-rigid Ureterostomy Market Research Report – Forecast to 2023

                                                                                Key words

Global Flexible & Semi-rigid Ureterostomy Market Research Report, by Product Flexible Ureter scopes, Semi-rigid Ureter scopes, Application ,Therapeutic Applications

Summary

Global Flexible & Semi-rigid Ureterostomy Market Research Report, by Product Flexible Ureter scopes, Semi-rigid Ureter scopes, Application Therapeutic Applications, End-User Hospitals, Clinics, Ambulatory Surgical Centers– Global Forecast Till 2023

 Body

The flexible and semi-rigid ureterostomy market is expected to witness tremendous growth owing to the rising prevalence of kidney cancer, kidney stone, and change in lifestyle. Other key factors such as the growing consumption of alcohol, change to sedentary lifestyle, increasing dehydration, and obesity are contributing towards the growth of the market. According to the University Hospital Southampton NHS Foundation Trust, March 2016, the prevalence of renal stone treatment increased between 5 to 10% with a 75% increase in obese patients. However, factors such as high cost of ureterostomy procedures are expected to hinder the market growth during the forecast period.

Segmentation

The global flexible and semi-rigid ureterostomy market is segmented on the basis of product, application, and end-user. The flexible and semi-rigid ureterostomy market, by product, is categorized into flexible ureter scopes, semi-rigid ureter scopes, and rigid ureter scopes. Flexible ureter scopes are further segmented into fiber optic ureter scopes and digital ureter scopes. On the basis of application, the market is segmented into therapeutic applications and diagnostic applications. Therapeutic applications are further segmented into urinary stricture, urolithiasis, and kidney cancer. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, ambulatory surgical centers, research centers, and others.

 Sample Report https://www.marketresearchfuture.com/sample_request/6469

 Regional Analysis

The Americas leads the market owing to the increasing prevalence of urolithiasis, increasing research and development programs in flexible video-ureter scopes, and growing healthcare expenditure. The American Urological Association, July 2016, has estimated a 3% prevalence rate for kidney stone in all individuals and stated that it affects 12% of the population during their lifetime. Such a high rate of kidney stone drives the market growth in this region.

Europe is expected to be the second largest flexible and semi-rigid ureterostomy market during the forecast period. The increasing occurrence of kidney cancer and obesity drive the market in this region. According to Cancer Research UK in 2015, there were12,547 new cases of kidney cancer. Thus, the growing cases of kidney cancer facilitate the market growth.

Asia-Pacific was estimated to be the fastest growing region for the global flexible and semi-rigid ureterostomy market in 2017. The market is expected to witness high growth owing to the rising prevalence of obesity and kidney cancer in this region. According to the National Center for Biotechnology Information publication 2016, 121,099 cases of kidney cancer were recorded in Asia in 2012 in which 66.12% patients were males. Such a high prevalence of kidney cancer influences the market growth.

This is expected to provide favorable backgrounds for the market to grow.

The Middle East and Africa accounts for the low share due to lack of awareness, low per capita income, and lack of well-trained healthcare professionals. However, the rising oncology and health care services in hospitals and in the community are expected to influence the market in a positive way.

Key Players

Some of the key players in the global flexible and semi-rigid ureteroscopy market are Stryker (US), Olympus Corporation (Japan), Boston Scientific (US), Richard Wolf (Germany), KARL STORZ (Switzerland), ELMED Medical Systems (Turkey), Maxer Endoscopy (Germany), Rocamed (France), Vimex Endoscopy (Poland), ProSurg (US), and others.

   Market scenario

Ureterostomy is a procedure used by urologists to diagnose kidney stones or problems related to the urinary tract. It is usually used in detecting kidney stones in the ureter. While performing ureterostomy, doctors insert a thin and flexible device into the ureter and bladder (carries urine from kidneys to bladder) to look for the problem. The global flexible and semi-rigid ureterostomy market is expected to register a CAGR of 5.4% by 2023.

The advancements in surgical techniques and technology have broadened the range of urologic conditions into urothelial carcinoma, renal and ureteric calculi, and ureteral structures.

It is mainly observed in males in the age group of 50 to 80 years than in females. According to the National Center for Biotechnology Information, January 2016, 44% of ureterostomies were performed by using flexible ureterostomies, 31% by rigid ureterostomies, and 25% by associated rigid and flexible ureterostomies. It was also reported that the urinary stone disease is affecting 3 men to 1 woman, between the age of 40 and 50. The major key factors responsible for influencing this market are increasing dehydration, digestive diseases and surgery, increasing obesity, family history related to kidney problems, and other medical conditions. Other conditions could be certain diets such as eating high in protein-sugar and sodium (salt) which may increase the risk of some types of kidney stones. However, factors such as the high cost of surgical procedures and difficulty in cannulation and identification of ureteral NB orifice are expected to restrict the market growth during the forecast period.

About Markets research future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members

  .

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +16468459312

Email: sales@marketresearchfuture.com

[newsintodays-blog]

IVF kids may have higher risk of high blood pressure

New Post has been published on http://newsintoday.info/2018/09/09/ivf-kids-may-have-higher-risk-of-high-blood-pressure/

IVF kids may have higher risk of high blood pressure

(Reuters Health) – Kids born through in vitro fertilization may be more likely to develop high blood pressure, a new study suggests.

FILE PHOTO: A doctor injects sperm directly into an egg during in vitro fertilization (IVF) procedure called Intracytoplasmic Sperm Injection (ICSI) at Novum clinic in Warsaw October 26, 2010. REUTERS/Kacper Pempel

Researchers found a higher average blood pressure among teens born through IVF than in children conceived naturally, according to a report in the Journal of the American College of Cardiology.

Moreover, teens born through IVF were more likely to have blood pressures high enough to be diagnosed with hypertension.

The researchers advise parents of children conceived with IVF to concentrate on other heart disease risk factors.

“Eliminate additional cardiovascular risk factors, such as overweight, sedentary lifestyle and smoking,” suggests coauthor Dr. Urs Scherrer of the University of Bern, Switzerland. Also, he recommends, get a 24-hour blood pressure reading when the children are between ages 16 and 20.

Scherrer and colleagues compared 54 teens conceived through IVF with 43 of their friends who had been conceived naturally. The teens’ average age was 17.

In adults, a blood pressure above 120/80 is considered high. But in children and adolescents, a normal blood pressure depends on age and height. If a youngster has a higher blood pressure than 90% to 95% of other males or females his or her age and height, then the child may have high blood pressure.

The IVF teens had higher blood pressure, on average, than their friends (119/71 versus 115/69). Eight of the IVF teens were diagnosed with hypertension, compared to one in the control group.

Five years earlier, researchers had checked blood pressures in both groups and found no difference between IVF teens and their friends. “Until adolescence there are no cardiovascular problems,” Scherrer said by email.

The conditions under which IVF embryos develop may play a role, he suspects.

“There are numerous conditions which are not physiologic during the in vitro period – temperature, mechanical insults related to embryo handling, sub-optimal culture media, etc. – that the embryo needs to cope with in order to survive, (and these) may have altered the regulation of gene (expression),” Scherrer said.

While the new findings are very interesting, the study is small, said Dr. Alan Penzias, an associate professor of obstetrics, gynecology and reproductive biology at the Harvard Medical School and a fertility specialist at Boston IVF.

Findings of small studies are not always generalizable to the population at large, Penzias said by email.

And while the researchers may have mitigated a number of possible confounders by using the IVF children’s friends as controls – the control group was probably the best match for socioeconomic background, for example – they didn’t eliminate what might have been the biggest variable: history of infertility, Penzias said.

“Is the finding in this paper caused by the IVF procedure or is it caused by the infertility itself,” Penzias asked.

Penzias points to a large 2012 study in the New England Journal of Medicine that found a higher risk of birth defects in babies born to couples with a history of infertility, regardless of whether the babies were conceived naturally or with IVF.

Still, Penzias said, “tracking the outcomes of medical intervention is prudent. Deciphering the mechanisms of disease to facilitate the design of treatments that improve the human condition is a worthy mission and is one that is universally endorsed.”

SOURCE: bit.ly/2NkKe3w Journal of the American College of Cardiology, online September 3, 2018.

Our Standards:The Thomson Reuters Trust Principles.

Source link

[swissforextrading]

The Future of Digital Health

The health technology landscape is evolving — and that’s causing a major shift in perspectives that will impact how we imagine access to services, health data collection, and the role of wellness and prevention. Switzerland is a leader in life sciences and digital trust, and from swissnex San Francisco’s unique position, we bridge an understanding of Swiss markets with our access to future trends and tech from a US perspective. This article examines the technology driven shifts in healthcare that could transform the landscape: from data analytics to customer experience, turning data into action (as with Blockchain), and the shift from patient to consumer-driven engagement. We’ll check in on Apple and Google as they offer roadmaps to the emergent futures of healthcare, with an eye toward how Switzerland fits in. Two Baselines of Trust        Large Swiss organizations, such as Swiss Post, interact physically with Swiss households on a daily basis. This has led them to develop diverse product offerings that draw upon what I call “explicit trust.” This trust is a line across all of Swiss Post’s services: from delivering the mail to delivering financial services. Without trust, Swiss Post could not be responsible for assuring services such as reliable bus services, E-voting, health parcel delivery or digital health records. This consistent and persistent interaction with Swiss households can be juxtaposed with a more common issue for a technology company: the need to establish trust on a user by user basis, in an entirely digital manner, practically every time they engage. So that even though a user may “implicitly trust” the technology and the company to provide a solution, they have not had the benefit of trust-based engagement across time. This has a big impact on the health technology industry, which is beginning to reframe these relationships. Traditionally, people interacted with a small group of healthcare providers. The conveniences of digital healthcare move users toward interactions with multiple providers and practitioners. This asks users to shift their baseline from “trusted person” to “trusted party.”   Incumbents in the digital health market have the clear advantage here. Why? Because even in the midst of a mobile solutions and a telemedicine marketplace boom, patients still prefer digital health care when it is delivered from known medical practitioners. As healthcare providers enter the technology space, they will come to market with the benefit of patient preference and economies of scale on their side: that means a greater agility as they move from “trusted person” to “trusted party.” For startups, being mindful of this person-to-party transformation can help steer into a radical shift in the market for patient-generated data. Currently, health outcomes and advice are formed after a brief interaction with a physician. But the data any user produces from their personal device is implicitly trusted. Connect these dots and you see the opportunity for meaningful, informed action based on device-driven data that could bolster a “new” experience with a new provider. There is a clear market for technology that bridges this trust into new spaces, not only measuring and improving health outcomes, but by linking or combining that data with access to health practitioners. It will be interesting to see how Alphabet’s “study watch“ will impact this market, as well as the notion of “health service on demand”, that is, connecting personal health data devices via a driverless vehicle network while commuting. AI and Data Analytics AI solutions are poised to revolutionize predictability, diagnosis, monitoring, and treatment protocols. Alphabet, Google’s parent, is investing heavily in this market through its subsidiaries Verily and DeepMind.  Mobile service solution providers, virtual visits, and outpatient services (data heavy, but working better in aggregate) are shifting patient service delivery. Collaboration drives adoption. Digital therapeutics options — for example, Akili, an AR/VR solution for treatment of ADHD; and Coclear, an over-the-counter hearing aid with an app driver thanks to loosened FDA approval mechanisms — are the result of this new understanding. But data cleanliness and data breach remain major concerns as users are asked for increased access to digital health records. I don’t believe society would be as passive in its response to an Equifax-like breach of our collective health records. Blockchain Solutions  It’s hard to imagine an aspect of health data / systems management that couldn’t benefit from blockchain. Health data sets are incredibly useful when pooled, which lends itself perfectly to distributed ledger technology. Governance protocols (such as clinical audits, education, training, grievances), hospital logistics and supply chain management (including traceability) — all point to blockchain solutions. Blockchain could help to establish the identity of a patient for treatment, ensure accurate billing, or share access to medical records only with permissioned parties. Blockchain could lead to tools that put health data into action, for example, by building data marketplaces where multiple medical facilities can share access to patient records. Could a robust API marketplace create the same result? Possibly. But blockchain solutions provide the interoperability, scale, and security that an API strategy falls short of in the long game. To be actionable, health data first must be satisfactorily anonymized. We might be understandably spooked in the light of the recent Cambridge Analytica scandal and Facebook’s pullback from its own anonymized data testing (even though this initiative was led by a Stanford Cardiologist). The current climate of the market suggests that patient centricity is “in” and doctor centricity is “out.” As we move toward patient-generated data sets that interface with multiple service providers, there is certainly room for patients and doctors to share the benefits. However, this amplifies the need to link patient compliance, engagement, communication, satisfaction and grievance within an interoperable framework. When it comes to anonymity and trust, Switzerland is uniquely positioned in the market. The Swiss have a clear understanding of both private-cloud and on-premise data solutions, all within the deep regulatory framework a global health marketplace demands. Consumer-Driven (not Patient-Driven) The Insurance reimbursement process has been reimagined. Today we see a shift from fees for services to fees for outcomes. This has led to a significant uptake in remote patient monitoring and engagement. Fundamentally, consumers are paying more for healthcare, not the insurance company. With the announcement of the Amazon/Berkshire Hathaway/JP Morgan partnership, it is impossible to think that Amazon won’t take aim at the cost of access, with the consumer as the real target. Moreover, Apple recently announced it would launch its own primary care health clinics called AC Wellness. A second recent development is the Aetna/CVS health merger, where the second largest US health insurer was acquired by pharmacy chain CVS. CVS stated the goal of the merger was to remake the consumer health care experience. CEO Larry Merlo said, “with the analytics of Aetna and CVS Health’s human touch, we will create a health care platform built around individuals.” Moving from a health care system focused on illness toward a culture of health could be a byproduct of technology marketplace advances and patient-centric data aggregation. Anthem explored a retail health partnership with Lucky supermarkets in 2010/11 by setting up wellness centers through in-store Pharmacies in Northern California. They might have been early to market, but that offering fell short of expectations. Indeed, Anthem had recently inked their own deal with CVS to start its own pharmacy benefit management platform (InginioRx), a deal which could now be off of the table. Are these activities driven by a desire to own patient data under the guise of patient engagement? Perhaps we’ll see from the outcomes. Hello Apple Wellness is core to Apple’s growth strategy. Activity, mindfulness, nutrition, and sleep are essential to their new business model. Hardware (wearables) + Software (app store) + Secure storage (iCloud) provide a scalable framework. With cash on hand and 40% global mobile device penetration (86m iPhones) Apple has clear advantages in the health technology market, even when compared to market veterans such as United Healthcare’s 48m or Anthem’s 34m customers. Offering control of your personal health records, merging personal data and actionable aggregate data, and pairing all that with consumer based products and services, is the baseline for a technology marketplace that reimagines health care. This is made even more powerful with the loosening of FDA regulations on consumer devices, and Apple’s patents on EKG, glucose and heart monitoring, etc. Apple’s massive, active customer base can deliver sets of qualified registrants for research. A recent call for participation in a Stanford health study on care coordination for chronic disease delivered 11k sign ups in one day — a feat that otherwise requires a year of coordination from dozens of medical centers to provide qualified candidates. What’s NEXT? Can we speculate on a future for health technology? Consumer technology advances will drive down healthcare costs, and triggers will emerge with the consumer at the center of their own health outcomes. How we access health practitioners will be facilitated by voice interfaces, including vocal analysis for symptoms like pain and stress. Japan will lead the way in aging care, and whoever cracks the code to reduce these costs in the global market wins a massive prize.  AI will revolutionize diagnostics, prevention, monitoring and treatment protocols. And finally, look out for the doctor robot coming to a pharmacy near you. --- Photo: CC-0 via Pixabay. https://nextrends.swissnexsanfrancisco.org/the-future-of-digital-health/ (Source of the original content)